OSE Immunotherapeutics

31 articles with OSE Immunotherapeutics

• 

  BioSpace Global Roundup, Sept. 5

  9/5/2019

  Companies from across Europe and Asia share updates on their business and pipelines.
• 

  BioSpace Global Roundup, July 25

  7/25/2019

  Biotech and pharma companies from across the globe provide updates on company strategy and pipeline developments.
• 

  BioSpace Global Roundup, July 18

  7/18/2019

  Pharma and biotech companies from across the globe provide updates on their pipelines and corporate strategy.
• 

  BioSpace Movers and Shakers: Dec. 26

  12/26/2018

  Companies closed out the year with a number of appointments and hires to strengthen their leadership teams, including changes at the FDA, Melinta, CLSA, Virion, and more.

• OSE Immunotherapeutics Announces Publication in Nature Communications on Anti-IL-7 Receptor Antagonist (OSE-127)

  10/29/2018

  Full Antagonist Mechanism of Action Demonstrated In Vivo

• 

  Boehringer Ingelheim and OSE Immunotherapeutics Ink $1.4B Deal

  4/5/2018

  Boehringer Ingelheim and OSE Immunotherapeutics signed a collaboration and license deal to jointly develop OSE-172 for myeloid cancers.

• OSE Immunotherapeutics Receives Notice of Allowance for New Patent by U.S. Patent and Trademark Office that Further Strengthens Intellectual Property Portfolio Around Tedopi in Immuno-Oncology Applications

  1/25/2018

  The new patent extends the U.S. protection of Tedopi to several combinations of neoepitopes (peptides from various tumourous antigens optimized to bind strongly with HLA-A2 and T lymphocyte receptors) for use in cancer treatment.

• OSE Immunotherapeutics Presents New Data Analysis Supporting Continued Development of OSE-127 in Inflammatory Bowel Diseases

  12/19/2017

  The presentation reported results from a transcriptomic analysis of colon biopsies in more than 500 patients and 100 controls in a large database available for specialized bioinformaticians. 

• OSE Immunotherapeutics Receives a Grant From French Government Program "Fonds Unique Interministériel" to Explore New Cytotoxic Antibodies

  12/15/2017

  This collaborative program is focused on developing innovative tests to explore and to measure the cytotoxicity of monoclonal antibodies.

• OSE Immunotherapeutics to Resume Accrual in Phase III Clinical Trial of Tedopi in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment

  12/7/2017

  There continue to be no safety concerns, as safety data remain similar to what was expected for Tedopi® based on the results of previous clinical trials.

• OSE Immunotherapeutics Publishes New Data on FR104, CD28-Antagonist Immunotherapy

  10/19/2017

  FR104 shows immune tolerance superiority over CTLA4-Ig in humanized skin transplant model.

• Selexis SA And OSE Immunotherapeutics Expand Strategic Alliance To Further Advance OSE’s OSE-172 And OSE-703 Cancer Immunotherapy Programs

  9/26/2017

• OSE Immunotherapeutics Announces Temporary Pause Of Patient Accrual While Continuing Treatment For Patients Already Enrolled In Phase III Clinical Trial Of Tedopi In Advanced Lung Cancer

  6/26/2017

• OSE Immunotherapeutics Presents Positive Preclinical Results And Human Ex Vivo Data For OSE-127 (Effi-7) To Support Next Clinical Applications In Inflammatory Bowel Diseases At The Federation Of Clinical Immunology Societies (FOCIS) Conference

  6/15/2017

• OSE Immunotherapeutics Announces Results Of 2017 Annual Meeting Of Shareholders

  6/14/2017

• OSE Immunotherapeutics Announces Strategic Multi-Year Research Collaboration With Memorial Sloan-Kettering Cancer Center In New York

  6/12/2017

• Selexis SA And OSE Immunotherapeutics Sign Commercial License Agreement To Further Advance Development Of OSE's Interleukin Receptor 7 Antagonist

  5/23/2017

• OSE Immunotherapeutics To Present At Annual Sachs Immuno-Oncology: BD&L And Investment Forum

  5/18/2017

• OSE Immunotherapeutics Presents New Data On Anti-SIRPa (Effi-DEM), The Checkpoint Inhibitor Blocking Pro-Tumor And Suppressor Myeloid Cells At “Advances In Immuno-Oncology Congress,” London, May 15-16, 2017

  5/15/2017

• OSE Immunotherapeutics Presented New Data At AACR Annual Meeting 2017 On OSE-172 (Effi-DEM), Company's Checkpoint Inhibitor Blocking Suppressive Myeloid Cells And Inducing Antitumoral Potent T Memory Response

  4/5/2017